algeta asa ( algeta : no ) was founded in 1997 by roy h. larsen and øyvind s. bruland in oslo , norway as a private biotechnology and pharmaceutical company .

the company ’s research and development focus lies in the field of alpha-particle emitting radiopharmaceuticals .

the lead product of the company , xofigo is the first marketed alpha-particle emitting radiopharmaceutics for cancer treatment .

algeta

a fund that is the company’s largest shareholder and senior algeta managers , together representing 14 percent of algeta’s share capital , planned to accept , algeta said .
“we believe the offer recognizes the strategic value of algeta and delivers a considerable cash premium to our shareholders . ” stein holst annexstad , algeta’s chairman , said .
7 . buyer : bayer target : algeta price : $ 2 . 9 billion
bayer wins cancer firm algeta with raised $ 2 . 9 billion bid | reuters
algeta said on thursday that its board unanimously recommended shareholders accept bayer’s sweetened offer .
for more : fda oks pinpoint prostate cancer radiation drug xofigo from bayer , algeta bayer bags algeta ' s cancer drug portfolio for $ 2 . 9b bayer ' s $ 2 . 4b bid to buy algeta fits neatly with cancer drug strategy
bayer bags algeta ' s cancer drug portfolio for $ 2 . 9b | fiercebiotech
an algeta buyout , though , would fall right into bayer ' s comfort zone .
bayer in talks to buy cancer partner algeta for $ 2 . 4 billion - livemint
algeta us and bayer healthcare are co - promoting the product in the us . bayer paid a €50m milestone payment to algeta following the launch of the product in the us .
algeta was advised by bioscience managers limited ( london , uk ) during this financing round .
bayer to acquire norway ' s algeta for cancer drug xofigo in $ 2 . 9b deal
bayer to acquire drug maker algeta in $ 2 . 9 billion deal - the new york times
stein holst annexstad , chairman of the board of directors of algeta , added : ' we believe the offer recognises the strategic value of algeta and delivers a considerable cash premium to our shareholders .
) has won backing from the board of algeta algeta . ol , its partner for a new prostate cancer treatment , for an increased $ 2 . 9 billion offer to buy the norwegian company .
shares of algeta rose 1 . 5 percent to 359 norwegian kroner in trading early tuesday in oslo .
updated : bayer ' s $ 2 . 4b bid to buy algeta fits neatly with cancer drug strategy
algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha - pharmaceutical platform . the company is headquartered in oslo , norway , and has a us subsidiary , algeta us , llc , based in cambridge , ma performing commercial marketing operations in the us . algeta is listed on the oslo stock exchange ( ticker : algeta ) . for more information please visit urltoken .
bayer to acquire norway ' s algeta for cancer drug xofigo in $ 2 . 9b deal | ubc
algeta’s largest shareholder , the venture capital firm healthcap , and algeta’s directors have agreed to tender their shares . the transaction is subject to regulatory approval and shareholders must tender a minimum of 90 percent of the company’s stock .
goldman sachs is algeta’s financial adviser , and skadden , arps , slate , meagher & flom and wikborg , rein & co . are acting as algeta’s legal advisers . deutsche bank served as bayer’s financial adviser on the transaction .
algeta scientists showed that injections of radium into the blood led to a concentration in bone and a positive impact on patient survival . from 2004 , abingworth followed algeta closely before leading a major recapitalisation of the company in 2009 .
updated : bayer ' s $ 2 . 4b bid to buy algeta fits neatly with cancer drug strategy | fiercebiotech
) has clinched a $ 2 . 9 billion deal to take over norwegian cancer drug maker algeta algeta . ol after being tendered 92 . 17 percent of the shares in a cash offer , the companies said on monday .
bayer has reached an agreement to buy norwegian pharma company algeta after raising its offer to around $ 2 . 9bn .
bayer’s increased bid is at a 48 percent premium to algeta’s three - month volume weighted average stock price on november 25 .
the offer , which is expected to go to algeta shareholders in january once it has been cleared by the oslo stock exchange , is subject to a minimum acceptance of 90 percent of algeta’s share capital , as well as approval by antitrust authorities .
management of the two companies have now agreed a nok 362 per share deal for algeta , which will now be offered on a voluntary basis to the norwegian firm ' s shareholders . the bid represents a premium of 37 per cent over algeta ' s closing price on november 25 when the initial offer was made . this morning algeta was trading at around nok 359 .
bayer is offering algeta shareholders a smaller premium than other biotechnology companies have gotten over the past five years . photo : bloomberg
algeta is also developing other technologies for delivering alpha - pharmaceuticals . these include methods to enhance the potency of therapeutic antibodies and other tumor - targeting molecules by linking them to the alpha particle emitter thorium - 227 . the company is headquartered in oslo , norway , and was founded in 1997 . algeta listed on the oslo stock exchange in march 2007 ( ticker : algeta ) .
- potential deal value of $ 800 million ( eur560m * ) plus tiered double digit royalties - algeta to receive $ 61 million ( eur42 . 5m ) cash upfront , followed by development and sales milestones - algeta retains option for co - promotion and profit - sharing in usa - algeta and bayer will jointly develop alpharadin , with bayer contributing a substantial majority of the costs of future development
in september 2009 , algeta entered into an global agreement with bayer healthcare ag for the development and commercialization of alpharadin . as part of the agreement , algeta retains an option to co - promote alpharadin in the united states and to share profits from future sales .
algeta asa ( ose : algeta ) , the cancer therapeutics company , announces today that it has entered into a global agreement with bayer for the development and commercialization of algeta ' s first - in - class alpha - pharmaceutical , alpharadin . alpharadin is currently being evaluated in a global phase iii trial in men with hormone - refractory prostate cancer ( hrpc ) that has spread to the bone .
the uk future technologies fund contributed to the fund . in addition to avila advent has backed cellnovo , respivert , thiakis and algeta .
bayer has won the backing of the board of directors of algeta to support its bid to acquire the norwegian developer of cancer drugs .
algeta asa is a cancer therapeutics company built on world - leading , proprietary technology . algeta is developing a new generation of targeted cancer therapeutics ( alpha - pharmaceuticals ) that harness the unique characteristics of alpha particle emitters and are potent , well - tolerated and convenient to use .
“when the company was bought by bayer , there were a lot of competencies and resources that were allocated to other promising companies . so other companies can capitalize on [ the worked performed in algeta ] . the inventors of algeta have started two new companies , ” benedicte bakke explains .
the bayer group plans to further strengthen its oncology portfolio with the acquisition of norwegian pharmaceutical company algeta asa , oslo , according to a press release . bayer has already collaborated with algeta to develop and commercialize the cancer drug xofigo . the planned acquisition would give bayer full control over xofigo .
the first commercial sale of xofigo triggers a eur 50 million milestone payment to algeta from bayer under the terms of the 2009 development and licensing agreement . bayer has worldwide exclusive marketing rights for xofigo . algeta us , llc and bayer healthcare are co - promoting the product in the us .
in september 2009 , algeta signed an agreement with bayer for the development and commercialization of xofigo . under the terms of the agreement , bayer will develop , apply for health authority approvals worldwide and commercialize xofigo globally . algeta us , llc is co - promoting xofigo with bayer in the us .
algeta said in march that there was broad industry interest in its thorium - 227 technology . thorium - 227 is an alpha - particle emitting element that can be linked to monoclonal antibodies to create localized tumor - killing cancer treatments . algeta is working with sanofi , ablynx nv , affibody ab and
for bayer , algeta fits with chief executive marijn dekkers’ strategy of driving growth by building up the pharmaceuticals division , which now overshadows chemicals in importance .
oslo , norway - - march 26 , 2007 - - algeta asa , the norwegian cancer therapeutics company , today announced the successful closing of its initial public offering . the offering was more than two times oversubscribed and was priced in the upper half of the price range at nok 47 per share . gross proceeds ( before over - allotment ) amount to nok 250 million ( $ 41 million ) . the offering took place in conjunction with algeta’s listing on the oslo stock exchange . algeta shares are expected to begin trading on the oslo stock exchange ( ticker : algeta ) on tuesday , 27 march 2007 .
algeta won the scrip award for biotech of the year in 2010 on the basis of it signing one of the largest partnering deals of the year in oncology with bayer . algeta also won breakthrough of the year at the european mediscience awards in 2012 following its successful phase 3 results and progress towards launch .
norwegian biotech algeta asa has licensed bayer schering pharma worldwide development and marketing rights to its phase iii cancer - targeting radiopharmaceutical alpharadin ( radium 223 chloride ) .
xofigo project name : radium - 223 chloride disease : prostate cancer peak sales estimate : $ 1 . 5 billion approved : may 15 companies : bayer and algeta
in september 2009 , algeta signed an agreement with bayer for the development and commercialization of radium - 223 . under the terms of the agreement , bayer will develop , apply for health authority approvals worldwide and commercialize radium - 223 globally . algeta us , llc will co - promote radium - 223 with bayer in the us .
bayer’s sweetened bid at 362 norwegian crowns per share represents a 37 percent premium to algeta’s closing price on november 25 , the day before its initial offer became public .
advent invested in the series a in 2005 . algeta listed on the oslo stock exchange in march 2007 and was acquired by bayer in 2014 for $ 2 . 9b .
she points , for example , to the major investment fund healthcap , which is also a member of the cluster and has posted millions in both nordic nanovector and algeta .
from the left : andrew kay , ceo of algeta , trond giske , the norwegian trade and industry minister and eva dugstad , president of ife . photographer : ina wesenberg
the alpharadin deal with bayer totals up to $ 800 million ( eur560m ) to algeta . this is made up of an upfront payment of $ 61 million ( eur42 . 5m ) plus further cash payments based upon the achievement of certain development , production and commercialization milestones . algeta will be responsible for manufacturing and supply of the commercial product .
still , after bayer put down a 14 . 8 billion kroner ( $ 2 . 4 billion ) bid for oncology partner algeta , some analysts immediately predicted an uptick in price . algeta discovered xofigo , the recently approved radiotherapy for prostate cancer that has spread to the bone - - and bayer has pegged it as a $ 1 billion - plus drug . plus , algeta is working on more radiation - based cancer technologies , including an armed - antibody approach , and bayer wants to beef up its offerings in oncology .
algeta said on thursday that bayer , through a subsidiary , intends to launch a cash tender offer to acquire the outstanding stock of the company for 362 norwegian kroner , or about $ 59 . 13 , a share . the offer is a 37 percent premium on algeta’s closing price on nov . 25 , the day before the preliminary offer was announced .
the board of directors of algeta has unanimously decided to recommend acceptance of the offer to its shareholders . in addition , bayer has obtained pre - acceptances for approximately 14 % of the shares in algeta , including pre - acceptances from all members of algeta’s board of directors as well as from algeta’s largest shareholder , healthcap iv . bayer intends to make the offer through a subsidiary of bayer nordic se once the offer document has been cleared by the oslo stock exchange . the successful completion of the transaction is subject to certain conditions , including a minimum acceptance level of 90 % of the share capital and approval by the relevant antitrust authorities . bayer expects to close the transaction during the first quarter of 2014 .
the statement reinforces the view that bayer views the algeta acquisition as a platform rather than a product purchase , with additional radiopharmaceuticals in its pipeline including a programme in breast cancer .
‘ife has been an important partner to algeta throughout the clinical development of radium 223 , and it has been instrumental in helping us build a commercial production facility for the global supply of xofigo . we are all extremely grateful for the expertise , dedication and support that ife has provided to algeta on this journey and look forward to continuing our productive partnership . ’
algeta asa is a norwegian therapeutics company built on world - leading expertise in nuclear medicine and oncology and dedicated to the development of novel anticancer therapeutics based on alpha particle emitting radionuclides .
having worked with bayer since 2009 , the board of directors is convinced of bayer ' s commitment to establishing xofigo ( radium ra 223 dichloride ) globally , and maximizing its blockbuster potential ,
noted algeta chairman stein holst annexstad .
we are also pleased that bayer intends to further invest in the potential of algeta ' s targeted thorium conjugate research platform .
algeta received a preliminary offer for 336 kroner a share , the oslo - based drugmaker said in a statement on tuesday , following a report on the approach by german newspaper frankfurter rundschau . the proposal values algeta at 27 % more than monday’s closing price of 264 . 6 kroner . the shares rose to 345 . 20 kroner , suggesting investors expect a higher bid .
upfronts , milestones and royalty payments according to the agreement between bayer and algeta will be in eur . usd amounts provided in this release have been translated at 1 euro : usd1 . 43
bayer’s shares were up 1 percent , while algeta’s rose 1 . 5 percent by 5 : 21 a . m . et in line with the stoxx europe 600 health care index . sxdp .
bayer acquired the drug through an $ 800 million deal with norway ' s algeta in 2009 , and the german pharma magnate is now hitching its oncology hopes to its partner ' s platform technology , paying $ 2 . 9 billion to buy out algeta last month . the deal gives bayer full control of xofigo and its blockbuster potential and includes a promising pipeline of similarly targeted therapies .
algeta was valued at nok 775m ( $ 125m ) at ipo in early 2007 – it was acquired by bayer for nok 17 . 6bn ( $ 2 . 9bn ) in march 2014 .
algeta had the biggest gain since 2011 , rising 30 % to close at a record 345 . 20 kroner in oslo . bayer fell 0 . 3 % to close at €95 . 79 .
algeta ' s lead product candidate , alpharadin , addresses a major market opportunity in the field of oncology . bone metastases are a devastating consequence of the progression of certain cancers and current treatments are largely ineffective . healthcap is very excited to be supporting the algeta team in their efforts to develop new therapeutics that target this important unmet medical need ,
said per samuelsson , partner at healthcap .
for further information , please contact : dr . thomas ramdahl ceo algeta asa + 47 23 00 79 90 mark swallow phd / helena podd citigate dewe rogerson + 44 ( 0 ) 207 638 9571
for more : special reports : the top 10 pharma companies by 2013 revenue - bayer healthcare with big 5 , bayer aims for 8 % annual pharma growth through 2016 new drugs in hand , bayer ' s pharma sales leap ahead with a sweetened $ 2 . 9b bid , bayer nabs its xofigo partner , algeta bayer bids $ 2 . 4b for xofigo partner algeta in drive for cancer growth
algeta signed an agreement with bayer for the development and commercialisation of xofigo in september 2009 . under the terms of the agreement , bayer will develop , apply for approvals worldwide and market xofigo globally .
by harnessing the unique characteristics of alpha emitters , such as high potency and short range , algeta is developing new therapeutic candidates and technologies targeting metastatic and disseminated tumors and promising unrivalled potency without unacceptable toxicities .
in december , bayer won backing from the target’s board for an increased $ 2 . 9 billion offer for the norwegian company , which is contingent on bayer being tendered 90 percent of algeta’s share capital .
john berriman , chairman of the board of algeta , said , “we are delighted to have successfully closed this offering , and very pleased to add so many international institutional specialist investors to our shareholder base . ”
algeta , a norwegian developer of treatments for cancer , has officially opened a commercial production facility for xofigo ( radium ra 223 dichloride ) at the institute for energy technology ( ife ) in kjeller , norway .
if you believe consensus , they should pay way more than that , van renterghem said . they should probably pay $ 3 billion . he raised his rating on algeta shares on tuesday to neutral from sell .
algeta asa , headquartered in oslo , norway , is a private therapeutics company dedicated to the development of novel anticancer therapeutics based on alpha particle emitting radionuclides . the company was founded in 1997 as anticancer therapeutic inventions .
thomas ramdahl , president and ceo of algeta , said : “with the recently announced phase ii data demonstrating a survival benefit for our lead product , alpharadin , algeta is at an exciting stage in its development . the funds raised from this offering will now allow us to accelerate the clinical development of alpharadin and advance our pipeline of preclinical product candidates towards the clinic . i look forward with confidence to continued progress in the future .
, a spokesman for bayer , confirmed that the leverkusen , germany - based company made a preliminary offer and declined to comment further . algeta said there’s no guarantee bayer’s proposal will result in a deal , and spokesman
oslo , norway - - ( marketwired - may 30 , 2013 ) - algeta asa ( ose : algeta ) announces that xofigo® ( radium ra 223 dichloride ) injection , recently approved by the us food and drug administration ( fda ) for the treatment of patients with castration - resistant prostate cancer , symptomatic bone metastases and no known visceral metastatic disease , has been launched in the united states and the first sale has been made .
the buzz over bayer ' s final price revolved entirely around xofigo , which is to be expected . but biotech insiders are likely to speculate that bayer also sees value in the work its collaborator was doing on new therapies . algeta was zeroing in on combining thorium - 227 with cancer - targeting antibodies for a next - gen pipeline . and algeta ' s board clearly expected a premium for the experimental work as well as xofigo .
in 2007 algeta completed its ipo on the oslo exchange . we took a small position at that time and engaged in active dialogue with the company . by 2008 , market conditions made it difficult to raise the additional money needed to start the pivotal phase 3 trial . in 2009 , we led a $ 37m financing in algeta having set the condition that the funding had to raise enough capital to complete the trials without a pharmaceutical partner .
bayer is offering algeta shareholders a smaller premium than other biotechnology companies have gotten over the past five years . acquirers paid an average 56 % premium in deals larger than $ 100 million , according to data compiled by bloomberg .
bayer and algeta are already partners in selling the prostate cancer drug xofigo , the use of which was approved by the united states food and drug administration in may . the companies have worked together on developing the drug since 2009 .
gross proceeds from algeta’s initial public offering , subject to completion , will amount to between nok 200 million and nok 250 million and will enable algeta to initiate a phase iii clinical program for alpharadin™ , the company’s lead product . alpharadin™ has , in a double - blind placebo - controlled phase ii clinical trial in patients with late stage prostate cancer , shown statistically significant survival benefit and significant results on various disease progression markers as well as a benign side effect profile .
bayer bid for algeta late last year to gain outright control over novel prostate cancer drug xofigo which the two have developed jointly since 2009 and started selling in the united states in 2013 . the drug also won european approval in november .
bayer has reached an agreement with algeta’s board of directors to make a recommended voluntary public takeover offer to algeta’s shareholders , and is offering them nok 362 per share in cash . the offer implies an equity value of nok 17 . 6 bn ( eur 2 . 1 bn ) and an enterprise value of nok 16 . 2 bn ( eur 1 . 9 bn ) . the offer price represents a premium of 37 % over the closing price on november 25 , 2013 , the day before algeta confirmed that it had received a preliminary , non - binding acquisition proposal from bayer , or a premium of 48 % over the unaffected three - month volume - weighted average share price on november 25 , 2013 .
radiopharmaceuticals specialist algeta asa , of oslo , norway , successfully closed its initial public offering , raising nok 250 million . the offering was more than two times oversubscribed and was in the upper half of the price range at nok 47 per share .
algeta ' s lead product candidate , alpharadin , is a novel bone - seeking experimental radiopharmaceutical based on the alpha particle emitter radium - 223 . alpharadin is currently in phase ii clinical trials as a potential new treatment for bone metastases from prostate cancer .
algeta developed xofigo® ( radium - 223 dichloride ) , a first - in - class , targeted alpha - pharmaceutical that was approved by the us fda and european ema for treatment of patients with symptomatic bone metastases secondary to castration - resistant prostate cancer .
algeta is also developing other technologies for delivering alpha emitters including microparticles , liposomes and its receptor targeting technology , which is designed to enhance the potency of therapeutic antibodies and other tumor - targeting molecules by linking them to the alpha particle emitter thorium - 227 .
bayer and algeta offer patient assistance through xofigo access servicessm which will assist with obtaining coverage and patient support of xofigo . patients and providers may contact the program at 1 - 855 - 6xofigo ( 1 - 855 - 696 - 3446 ) for additional information .
norway ' s algeta ended up negotiating a sales price that was 37 % over the share price it had rung up just ahead of the bid - - in line with the premiums that have been charged for biotech assets over the course of the year .
according to the senior advisor , international focus on the academic results created in norway has increased . she points to the german life science giant bayer ag’s takeover of norwegian biotech algeta in 2014 in a deal worth nok 17 . 6 billion as proof of that .
she refers to øyvind s . bruland and roy h . larsen , who worked on the early development of what would become xofigo and founded algeta in 1997 . since then , they have also helped found the company nordic nanovector in 2009 and oncoinvent the following year .
oncoinvent closed a funding round of its own recently , securing nok 210 million , and in a general sense , the funding environment in norway has improved immensely in recent years – not least due to the sale of algeta and a general recovery of the stock market .
the commercial production of xofigo is underway , and first doses are expected to be ready for patient treatment within a few weeks . bayer has worldwide exclusive marketing rights for xofigo . algeta us , llc and bayer healthcare will co - promote the product in the us .
news of bayer ' s interest in algeta - which developed recently - approved prostate cancer therapy xofigo ( radium ra 223 dichloride ) - first emerged in november when the offer was reported be nok 336 per share , valuing the company at around $ 2 . 4bn .
aside from the promising cancer medicine , algeta also had some 180 full - time employees . a number of those workers went with bayer to germany , while a portion of them stayed in the life science environment around oslo and some have moved on to other biotech companies .
a conference call for investors , analysts and the press , and hosted by algeta ' s senior management team , will take place tomorrow at 08 : 00 cet . to participate in the conference call , please dial the appropriate number below five minutes prior to the call :
the german healthcare giant , through aviator acquisition , a wholly - owned subsidiary of bayer nordic , has offered nok362 ( €43 ; us $ 59 ) per algeta share , in cash , valuing the company at approximately nok17 . 6bn ( us $ 2 . 9bn ) .
abingworth joined the board in 2009 . two us experts were then brought on to the board to oversee clinical and regulatory issues . investor relations advisors were engaged and banking introductions made to help internationalise awareness of the stock . in the first year after our investment the company signed an attractive deal with bayer where algeta retained rights to 50 % of the us market . the trial was well run and stopped early because of signs of overwhelming efficacy . bayer eventually acquired algeta and the drug , xofigo , is now available to patients in the us and europe
' having worked with bayer since 2009 , the board of directors is convinced of bayer’s commitment to establishing xofigo globally , and maximising its blockbuster potential . we are also pleased that bayer intends to further invest in the potential of algeta’s targeted thorium conjugate ( ttc ) research platform . '
oslo , norway , march 9 , 2007 - algeta asa , the norwegian cancer therapeutics company , announced today that the prospectus prepared for the forthcoming ipo and listing on the oslo stock exchange has been approved by ose . the book - building and application period starts monday , 12 march 2007 .
, and buying algeta would mean it doesn’t need to share profits or pay royalties on the medicine . the german drugmaker will probably need to spend more than it’s offering now for its partner , guillaume van renterghem , a london - based analyst for ubs ag , said in a telephone interview .
algeta is the quintessential biotech success story and testament to the range of communications skills and expertise that the citigate team can deploy to cover every likely situation during a company’s life cycle . at each stage , the communications focus was on addressing different challenges and business risks . planning for failure was as important as planning for success . as it was , the team was able to communicate algeta’s success more than its failings , including a major partnering deal with bayer , successful phase 3 results , approval by the regulators in the us and europe , product launch and the company’s eventual acquisition by bayer .
‘the recent approval and launch of xofigo in the us are momentous achievements for algeta and put us firmly on the path to deliver on our vision of becoming a world - class oncology company bringing novel targeted medicines to cancer patients through our leadership in alpha particle - emitting pharmaceuticals , ’ said kay .
algeta had a very intriguing idea . treatment of bone metastases includes irradiation with external x - rays but this is of limited patient benefit . what if you could get the source of radiation inside the bone and kill tumours locally ? radium 223 is a radioactive element that has chemical properties similar to calcium .
under the terms of the agreement , algeta has an option for up to 50 % co - promotion with bayer in the united states under a profit - share arrangement . bayer will commercialize alpharadin globally and pay tiered double - digit royalties on net sales in markets where there is no co - promotion .
germany ' s frankfurter rundschau initially broke the story , but it got the numbers wrong . in a statement , algeta confirmed an offer from bayer but said the bid was for 336 norwegian kroner per share , not 306 kroner , a 27 % premium that would value the company at $ 2 . 4 billion .
advent ' s life sciences team has a first - class investment track record . recent investments include avila therapeutics , biocartis , cellnovo , respivert , thiakis , algeta and amsterdam molecular therapeutics in all of which the advent life sciences team led the formation of the company and / or participated in the first venture round .
bayer’s offer values algeta at about 29 . 1 times earnings before interest , tax , depreciation and amortization , according to data compiled by bloomberg . acquirers of biotechnology companies paid an average of 24 . 4 times profit in deals of $ 100 million or more in the past five years , according to the data . bloomberg
it took a half - billion - dollar sweetener , but bayer has closed the deal to buy its cancer drug partner algeta for $ 2 . 9 billion in cash . the buyout leaves bayer with full control of the prostate cancer drug xofigo along with a pipeline that includes a potential next - gen successor to the targeted radioactive therapy .
andrew kay , algeta’s president & ceo , said : “we are delighted that the fda has taken the decision to approve xofigo so quickly . we are extremely pleased to be able to make this alpha particle - emitting pharmaceutical available to us patients with castration - resistant prostate cancer and symptomatic bone metastases . we will now finalize our launch preparations for xofigo in the us , with the intention of launching it , with bayer , as soon as possible . this approval is a major milestone for algeta and puts us firmly on the path to deliver on our vision to be a world - class oncology company bringing novel targeted medicines to cancer patients through our leadership in alpha particle - emitting pharmaceuticals . ”
the official ribbon cutting ceremony was attended by andrew kay , algeta ' s president and ceo , and senior management colleagues , who were joined by trond giske , the norwegian minister for trade and industry , eva dugstad , president of ife and andreas fibig , president and chairman of the board of management at bayer healthcare pharmaceuticals , and other guests .
earlier this year , bayer happily heralded the fda ' s approval of xofigo for castration - resistant prostate cancer as an important milestone for its steadily growing portfolio of cancer therapies . and now the german pharma company has set its sights on bagging algeta - - the norwegian company that discovered the therapy and subsequently partnered with bayer - - for $ 2 . 4 billion .
concurrent with the financing , per samuelsson , partner , healthcap ; patrick lee , general partner , advent venture partners ; and dr . kent gossett , principal , sr one ; will join stein annexstad , managing director , representing norgesinvestor ; dr . jens petter falck , partner , selvaag venture capital ; and john berriman , chairman ; on algeta ' s board of directors .
now , some analysts say the german pharma may have bid too high , but bayer may well find that algeta was worth the price . the company is working to beef up its oncology presence , and its other cancer partner - - onyx pharmaceuticals , which co - markets stivarga and the older nexavar - - was snapped up by amgen ( $ amgn ) last summer .
algeta ' s president & ceo , andrew kay , commented :
we are delighted to announce the first sale of xofigo , following its approval by the fda for the treatment of patients with castration - resistant prostate cancer , symptomatic bone metastases and no known visceral metastatic disease . for these patients , we anticipate that xofigo will be an important and welcome new addition to the treatment paradigm .
the therapy is used for the treatment of men with castration - resistant prostate cancer ( crpc ) who also have symptomatic bone metastases and no known visceral metastases , and racked up third quarter sales of around €12m ( $ 17m ) in the third quarter . algeta chief executive andrew kay said last month the drug had shown
excellent momentum
thanks to rapid endorsement by the us national cancer network .
alpha emitters have not until recently been a significant therapeutic modality . however , discoveries in radiochemistry and recent advances in the understanding of tumor and radiation biology led algeta ' s scientific founders - - roy larsen and oyvind bruland - - to conceive how the unique features of alpha emitters , such as high potency and short range , could be exploited to create new therapeutic candidates promising unrivalled potency without unacceptable toxicities .
not only has advent secured exits , its investee companies algeta a / s , eusa pharma inc . and uniqure nv have taken products through to approval , parekh noted , saying that underlines the importance of ensuring companies are adequately funded .
we are a big investor and we syndicate . early stage does not mean low cost ; you ' ve got to give companies enough capital ,
he said .
algeta may agree . in a statement , the norwegian company said discussions are at an early stage , and there is
no certainty
that a deal will materialize .
i think this company has great prospects on a standalone basis ,
cfo oystein soug told reuters . he wouldn ' t rule out a bidding war ,
but of course that is not my call ,
he said .
this press release is not for distribution to united states , canada or japan news services or for dissemination in the same countries or elsewhere where such dissemination is not appropriate . this news release is not and under no circumstances is to be construed as a solicitation , offer , or recommendation , to buy or sell securities issued by algeta . this press release may not be relied upon by any person to whom it was not intended to be provided . these materials are not an offer of securities for sale in the united states , canada or japan . securities may not be offered or sold in the united states absent registration or an exemption from registration under the u . s . securities act of 1933 , as amended . algeta asa has not registered , and does not intend to register , any portion of the offering in the united states
this press release is not for distribution to united states , canada or japan news services or for dissemination in the same countries or elsewhere where such dissemination is not appropriate . this news release is not and under no circumstances is to be construed as a solicitation , offer , or recommendation , to buy or sell securities issued by algeta . this press release may not be relied upon by any person to whom it was not intended to be provided . these materials are not an offer of securities for sale in the united states , canada or japan . securities may not be offered or sold in the united states absent registration or an exemption from registration under the u . s . securities act of 1933 , as amended . algeta asa has not registered , and does not intend to register , any portion of the offering in the united states .
john berriman , chairman of the board of algeta , said : “we are delighted to have successfully closed this offering , and very pleased to add so many international institutional specialist investors to our shareholder base . i would like to thank all those involved in the ipo process for their hard work , but special thanks are due to thomas ramdahl and his team for their unstinting efforts since the very early days of the company . ”
bayer plans to strengthen its oncology portfolio with the acquisition of norwegian pharmaceutical company algeta , with which it has already collaborated to develop and commercialize the cancer drug xofigo . the deal , valued at $ 2 . 9 billion , will give bayer full control over xofigo .
we are absolutely convinced of the potential of this drug and the underlying technology to provide patients with innovative treatment options ,
commented bayer ceo marijn dekkers .
first up , algeta is developing thorium - 227 , technology that would allow it to link alpha radiation particles like xofigo to monoclonal antibodies , promising to further improve targeting for future cancer treatments . meanwhile , bayer is spending big to study xofigo in combination with other prostate cancer drugs , including johnson & johnson ' s ( $ jnj ) fast - growing pill zytiga , looking to further expand the market for its banner injection .
algeta ' s lead product candidate , alpharadin , has completed one phase ii trial and is currently in two further phase ii clinical trials as a potential new treatment of hormone refractory prostate cancer . based on results to date , it is expected to progress to clinical phase iii trials . alpharadin is a novel bone - seeking radiopharmaceutical based on the alpha particle emitter radium - 223 and may potentially target skeletal metastases from multiple cancer types .
this news release contains certain forward - looking statements that are based on uncertainty , as they relate to events and depend on circumstances that will occur in the future and which , by their nature , may have an impact on results of operations and the financial condition of algeta . such forward - looking statements reflect our current views and are based on the information currently available to algeta . algeta cannot give any assurance as to whether such forward looking statements will prove to be correct . these forward looking statements include statements regarding our anticipated co - promotion of xofigo in the us . there are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward - looking statements . these factors include , among other things , risks or uncertainties associated with the ability to identify and hire a sufficient number of qualified employees in the us , growth management , general economic and business conditions and the pricing environment , the impact of competition , the ability to successfully commercialize xofigo , the risk that costs associated with the copromotion of xofigo may be greater than anticipated , manufacturing capacity , the risk of non - approval of patents not yet granted , risks in obtaining additional regulatory approvals for radium - 223 and the other risks and uncertainties described in our annual report .
this news release contains certain forward - looking statements that are based on uncertainty , as they relate to events and depend on circumstances that will occur in the future and which , by their nature , may have an impact on results of operations and the financial condition of algeta . such forward - looking statements reflect our current views and are based on the information currently available to algeta . algeta cannot give any assurance as to whether such forward looking statements will prove to be correct . these forward looking statements include statements regarding our co - promotion of xofigo in the us . there are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward - looking statements . these factors include , among other things , risks or uncertainties associated with the ability to identify and hire a sufficient number of qualified employees in the us , growth management , general economic and business conditions and the pricing environment , the impact of competition , the ability to successfully commercialize xofigo , the risk that costs associated with the co - promotion of xofigo may be greater than anticipated , manufacturing capacity , the risk of non - approval of patents not yet granted , risks in obtaining additional regulatory approvals for radium 223 and the other risks and uncertainties described in our annual report .
andrew kay , ceo of algeta , said ,
this agreement is the culmination of an extensive process to establish and deliver the best possible commercialization strategy for alpharadin . in bayer we have selected a world - class oncology company with a proven global track record of launching major cancer products . we are very excited about working with the bayer team to deliver this novel and potentially first choice treatment for cancer patients with bone metastases .
under its deal with bayer , algeta co - promotes xofigo in the u . s . and gets 50 % of the profits in - country ; outside the u . s . , it ' s eligible for royalties and milestone payments on bayer ' s sales . bayer is backing additional clinical trials testing xofigo in combination with johnson & johnson ' s ( $ jnj ) prostate - cancer pill zytiga and with various chemo drugs for other cancers .
after bayer bid $ 2 . 4 billion to buy algeta , some analysts predicted it would need to put down more to snag the oncology company . after all , the norwegian drugmaker discovered xofigo , one of bayer ' s shining growth prospects , and it has some other radiation - based cancer technologies - - including an armed antibody approach - - in the works . so bayer ponied up , chipping in another $ 500 million to seal the deal .
once word of bayer ' s initial $ 2 . 4 billion offer became public weeks ago , analysts expected that bayer would have to up its offer to the $ 3 billion zone if it expected to complete the acquisition . but a few have fretted that the company is paying a bit too much in the deal . algeta had retained co - promotion rights for the drug in the u . s . and had been due royalties on sales in europe .
algeta was also convinced there ' s a second act for xofigo ' s pinpoint alpha - radiation approach to treat cancer . the company has been zeroing in on combining thorium - 227 with cancer - targeting antibodies for a next - gen treatment , offering the potential for a subsequent step - up in its marketing activities . and while a 27 % premium would be considered rather thin this year , with stock prices and valuations up across the board , bayer can afford a bump in the price .
a tie - up would make good sense for bayer , which has been steadily building up its oncology work . the cancer division at bayer includes a partnership on nexavar and the second - generation therapy stivarga , now managed by amgen ( $ amgn ) following the onyx buyout . when algeta signed its $ 800 million collaboration deal with bayer 4 years ago , the savvy norwegian company kept its hands on co - promotion rights in the u . s . while carving out a royalty stream from bayer .
abg sundal collier norge and dnb nor markets acted as joint lead managers and terra securities has acted as co - lead manager . the issue comprises 5 , 319 , 148 new shares , and a further 797 , 852 shares have been allocated under the manager ' s over - allotment option . the issued share capital of algeta asa after the equity offering ( before over - allotment ) will be nok 8 , 231 , 654 , equalling 16 , 463 , 308 shares of nok 0 . 50 par value .
kemal malik , head of global development and member of the bayer healthcare executive committee said ,
we recognize the tremendous potential of algeta ' s alpharadin as a possible treatment for bone metastases in cancer patients - a serious , life - threatening condition . the data we have seen suggest that alpharadin represents a highly targeted treatment option with convenient handling and manageable side effects . bayer is committed to its global oncology franchise and has made significant progress in building a comprehensive pipeline of promising compounds that may provide innovative therapies to cancer patients in need of treatment .
oslo , norway - - ( market wire ) - - september 2 , 2005 - - algeta asa , a therapeutics company dedicated to the development of novel anticancer agents based on alpha particle emitting radionuclides , announced today the closing of a series a round of financing totaling nok 185 million ( euro 23 million / us $ 29 million ) . the funds raised will support the continued development of the company ' s lead product candidate , alpharadin , through its ongoing phase ii clinical trials and into pivotal phase iii trials as a potential new treatment for bone metastases arising from primary prostate cancer .
algeta ' s lead alpha - pharmaceutical candidate , alpharadin ( based on radium - 223 ) , has blockbuster potential for treating bone metastases arising from multiple major cancer types , owing to its bone - targeting nature , potent efficacy ( therapeutic and palliative ) and benign , placebo - like safety profile . development of alpharadin is most advanced targeting bone metastases resulting from hormone - refractory prostate cancer ( hrpc ) , and it entered an international phase iii clinical trial ( alsympca ) in mid - 2008 based on compelling clinical results from a comprehensive phase ii program . this trial is currently open for recruitment .
both of these drugs , however , are part of a partnership with onyx pharmaceuticals ( $ onxx ) , which amgen ( $ amgn ) snapped up in october . when amgen first moved in with its onyx bid , bayer was seen as a rival buyer . that obviously didn ' t come to fruition . algeta is more of a bite - sized deal , and thus would be easier to digest . and it falls within dekkers ' parameters for bolt - on acquisitions - - even if the price goes up to $ 3 billion . whether dekkers also believes bayer has wiggle room on price remains to be seen .
alpharadin is algeta ' s lead cancer therapeutic . it is the first in a new class of alpha - emitting pharmaceuticals ( ' alpha - pharmaceutical ' ) and is based on radium - 223 . alpharadin is in a global phase iii clinical trial ( alsympca ) designed to confirm its efficacy and safety as a targeted treatment for bone metastases in patients with hrpc . alpharadin is administered as a simple injection and has a unique mode of action whereby it targets bone metastases specifically and exerts a highly localized effect on tumor cells while minimizing damage to normal surrounding tissues . in phase ii studies , alpharadin demonstrated strong evidence that it can prolong patient survival , improve quality of life and offer a benign safety profile .
but bayer ' s embrace of algeta ' s cutting - edge approach to oncology is a sign that the old pharma isn ' t married to tradition , and , with ex - partner onyx pharmaceuticals taking a roughly $ 10 . 4 billion deal to join amgen ( $ amgn ) , bayer ' s timing couldn ' t be better . after promising to hone his company ' s oncology focus , bayer ceo marijn dekkers has come through with a blockbuster approval and a multibillion - dollar deal . now we ' ll see whether bayer ' s combination of bright minds and deep pockets can get it into the rare cancer company of roche ( $ rhhby ) , novartis ( $ nvs ) and amgen . - - damian garde ( email | twitter )
this news release contains forward - looking statements and forecasts based on uncertainty , since they relate to events and depend on circumstances that will occur in the future and which , by their nature , will have an impact on results of operations and the financial condition of algeta . there are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward - looking statements . theses factors include , among other things , risks associated with technological development , the risk that research & development will not yield new products that achieve commercial success , the impact of competition , the ability to close viable and profitable business deals , the risk of non - approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products .
advent life sciences closed its first dedicated fund at $ 158 million in 2011 . the final advent diversified fund , which closed in 2006 , so far has produced three new therapeutic products and two medical device products either brought to market by the portfolio companies themselves or their acquirers . some of its big exits or milestones include the $ 350 million acquisition of avila therapeutics by celgene in 2012 ; jazz pharmaceuticals’ $ 650 million purchase of eusa pharma in 2012 ; bayer healthcare’s $ 2 . 9 billion buyout of norwegian cancer drug maker algeta , which closed this year ; and the march 2014 ipo of versartis , of which advent owned 9 . 3 percent after the market debut . shares opened at $ 21 apiece and rose quickly at first , but have come back down below that initial mark , ending monday at $ 19 . 49 .


oliver peoples is an american luxury eyewear brand established in 1987 , and owned by luxottica .

the brand is sold in oliver peoples boutiques , online , and at fashion boutiques and department stores throughout the world .

oliver peoples eyewear is designed on la ’s sunset boulevard and handcrafted in italy .

oliver peoples

these glasses were exclusively available for purchase on the oliver peoples website and in oliver peoples boutiques .
oliver peoples sunglasses , $ 480 , bergdorf goodman , 888 - 774 - 2424 .
the son of oliver peoples founder larry leight worked for his father before becoming a competitor .
, oliver peoples is rereleasing one of its most popular styles , the op - 4 . it ' s part of the oliver peoples vintage circa 1987 collection , which commemorates the year the label was founded .
a subtle but distinctive feature of our sunglasses lenses that identifies oliver peoples is one of a kind breath logo .
under terms of the agreement , oakley will assume about $ 5 million in oliver peoples debt . oakley will pay an additional $ 4 million as an
earn - out incentive
for oliver peoples if it maintains its current performance .
gq : quick backstory . . . we know your father founded oliver peoples , but how’d you get into sunglasses yourself ?
larry and garrett leight , the minds behind oliver peoples and garrett leight california optical , are now gearing up for a new line of frames .
lessons by larry leight : i oliver peoples co - founder and creative director talks about the history of the company and product . video by the social trust
oliver peoples was founded in 1987 with the opening of its first boutique and launch of the original collection . from the beginning , oliver peoples had a passion for superior product , a distinctive culture rooted in california , and an obsession with service . these core values have remained at the foundation of the brand and endure today .
oliver peoples
m - 4
round metal sunglasses . vintage - inspired design reviving one of the first styles introduced in 1987 . hand - engraved feather pattern exclusive for
oliver peoples
m - 4 30th
round metal sunglasses . vintage - inspired design reviving one of the first styles introduced in 1987 . hand - engraved feather pattern exclusive
oliver peoples is recognized for its selection of superior polarized and photocrhomic mineral glass sun lenses , which combine the finest material available with the most advanced technologies in the world .
oliver peoples sunglasses from the 30th anniversary collection . black acetate and metal frames . pin detail at temples and frame front . eye / bridge / temple ( in mm ) :
oliver peoples was born in the heart of west hollywood , california , on iconic sunset boulevard . the unique culture of los angeles remains at the core of the brand’s dna .
each style in the oliver peoples collection is conceived and designed in the west hollywood headquarters , taking inspiration from everything including films , books , travel , magazines , and archival pieces .
brad pitt , as tyler durden , wears a pair of oliver peoples 523 sunglasses in the 1999 movie fight club . these glasses are extremely rare , and can now only be found on sites like ebay .
larry leight , chief executive , designer and co - founder of oliver peoples with his sister , dore chodorow , said the company ' s designs were inspired by the estate collection of oliver peoples , a 1920s - era optician , that leight acquired for about $ 6 , 000 . the company opened its first store on sunset boulevard in 1986 ; another of its five boutiques is at south coast plaza in costa mesa .
from 2006 to 2008 . i spent one year in between doing development because that was the only thing i didn & apos ; t do at oliver peoples . i was manufacturing eyewear for street - wear brands .
my dad started oliver peoples 25 years ago so he wasn & apos ; t doing sales . he didn & apos ; t know buyers and obviously the person that was working at oliver peoples wouldn & apos ; t give me that contact because they knew that i would compete with them . i had to be really resourceful . i literally opened the first 100 doors by looking at other brands that i liked and what doors they were in . obviously saying that my father did oliver peoples helped them say yes , but they liked the collection , too . . . i just had perseverance and i really wanted to build those personal relationships with my first 100 accounts .
since the debut of the first oliver peoples collection in 1987 , the same passion for the product , details , and finest materials has endured . each frame is handcrafted in a dedicated factory , with careful attention to detail .
while going through the inventory , he found a receipt belonging to the original owner , an eyewear distributor from the 1940s and ’50s named oliver peoples . “we were so excited , ” says leight , “we named the company after him . ”
we spoke with leight over the phone about how the oliver peoples connection benefited him ( as well as how it didn & apos ; t ) , getting into top retailers through sheer perseverance and confidence , the importance of collaborations and more .
by contrast , the oliver peoples name does not even appear on its eyewear . the company has depended on the word of mouth of celebrity owners such as tom cruise , johnny depp , jessica simpson and gwen stefani , and not on traditional advertising .
oliver peoples , the california - based , luxury eyewear brand celebrated their 30th anniversary with a star - studded crowd at the chateau marmont in los angeles this past friday . on the borders of the chateau ' s pool , guests mingled while previewing campaign installations by peter lindbergh , a contemporary german photographer best known for his simple , yet revealing portraits . with a dj performance by balthazar getty & charlie eisner , guests including campaign stars , levi dylan and monika ' jac ' jagaciak , jessica alba , angela lindvall , rebecca gayheart , brandon thomas lee , claire holt , dylan brosnan , black atlass , ethan peck , garance dore , danced the night away . oliver peoples 2017 campaign story
desert stories
can be viewed now on the oliver peoples website .
oakley inc . , whose high - tech sunglasses are worn by world - class athletes in several sports , said wednesday that it bought privately held oliver peoples inc . , whose classic spectacles have been seen on celebrities such as brad pitt and angelina jolie .
“when conceptualizing the campaign and story surrounding this milestone year for oliver peoples my mind went back to the beginning . when oliver peoples was founded in 1987 , the brand challenged the ostentatious eyewear trends of the era with its decidedly classic aesthetic , ” says creative director giampiero tagliaferri . “this was around the same time peter lindbergh was rising on the scene and changing fashion ' s view of beauty through his raw and minimalist photography . his ability to capture a story in his subjects ' eyes makes him a perfect fit to shoot eyewear . ”
oliver people
after midnight
round titanium sunglasses with linear engraving . 80 ' s inspired fashioned after the late nights in new york and
i think it ' s a good strategy . they are acquiring a brand that appeals to an entirely different consumer , and they can make oliver peoples more successful down the road ,
said analyst mitch j . kummetz of brokerage firm d . a . davidson & co .
larry leight , its patriarch , founded oliver peoples on the sunset strip in 1986 . the brand found its stride within months of its launch after magazine editors selected his styles to splash across spreads in vogue and vanity fair , prompting the jet set— elton john , christy turlington , spike lee , and claudia schiffer , to name a few—to sport the glasses . a pair of oliver peoples became immortalized when coveted by patrick bateman in bret easton ellis’s label - conscious yuppy satire american psycho . after 30 years at the helm , larry leight left the company last year .
the acquisition - - valued at $ 46 . 7 million , excluding the assumption of debt and incentives - - is the first in the 35 - year history of foothill ranch - based oakley . company executives said the deal with oliver peoples would enable oakley to extend its reach while remaining true to its own branding .
it was a simple thing of the community of venice not having a good optician and solving that problem . i worked there every day and hired a team . i didn’t have garrett leight [ the brand ] at the time but carried oliver peoples and other brands . that was in 2009 and the brand didn’t come until 2011 .
to celebrate its 30th anniversary , luxury eyewear brand oliver peoples tapped peter lindbergh to shoot a star - studded campaign . titled
desert stories ,
the narrative follows four friends—amber valletta , alex lundqvist , levi dylan , and jac—as they traverse the picturesque landscapes of the mojave desert and discover an oasis in the form of a rustic american diner .
: paul allen has mistaken me for this dickhead marcus halberstram . it seems logical because marcus also works at p & p ; and in fact does the same exact thing i do and he also has a penchant for valentino suits and oliver peoples glasses . marcus and i even go to the same barber , although i have a slightly better haircut .
as part of its 30th - anniversary celebrations , la - based eyewear brand oliver peoples has created a capsule collection in collaboration with contemporary french eyewear brand alain mikli . both have a decades - long history of making innovative shades that go on to define a generation . who could possibly forget alain mikli ' s slatted shades made internationally famous by kanye west ?
in fight club , brad pitt wears three different types of sunglasses in the movie ( all by oliver peoples : the aero , the op 523 , and the sunset , respectively ) . the op - 523 is by far the most popular ( and hard to get ! ) . check ebay where you can usually find a few pair for very high prices .
10th anniversary limited release celebrating the movie fight club ' s 10th anniversary , oliver peoples re - released tyler durden ' s signature sunglasses in 2009 . the 523 , out of production since 2000 , was available for a limited time in two color options : silver frame with blood - red glasses and gold frame with orange glasses . only 75 of each will be sold , so this will also be an instant collector ' s item .
i basically reverse - engineered an eyewear company : i worked at oliver peoples in every department . i learned what i needed to do , where to distribute it , how to market it . journalism is also a big part because we do a magazine that we release twice a year ; we have a tone of content on our site . we & apos ; re really focused on los angeles and telling the story from our point of view .
description oliver peoples
m - 4
round metal sunglasses . vintage - inspired design reviving one of the first styles introduced in 1987 . hand - engraved feather pattern exclusive for the 30th anniversary collection . lens / bridge / temple ( in mm ) : 47 - 20 - 145 . flat base g - 15 ? ? lenses with antireflective coating add a cool , progressive touch . silicone nose pads for comfortable fit . 100 % uva / uvb protection
here , the two combine aesthetic signatures for a truly summery capsule—just in time to hit the beach or jet set somewhere tropical . fittingly , mikli reintroduces a palm tree pattern ,
palmier ,
first created in 1987 , to two oliver peoples sunglass styles : gregory peck and remick . opting out of the traditional photography campaign , the two have tapped illustrator juanjo villalba bermudez to create a series of drawings that highlight what makes each pair of sunglasses unique .
description oliver peoples sunglasses from the 30th anniversary collection . black acetate and metal frames . pin detail at temples and frame front . eye / bridge / temple ( in mm ) : 48 / 24 / 145 . round rose golden mirror lenses . contrast two - tone arms . 100 % uv protection . can be fitted with prescription lenses . made in italy . proposition 65 warning : sunglasses contain bisphenol a ( bpa ) , a chemical known to the state of . . .
i definitely was pretty confident . we were also selling it in my store already maybe for three months and it was doing really well , so i was able to say ,
listen this stuff is selling , i & apos ; m in venice beach , it & apos ; s cool , there are movie stars who buy it and wear it and come back .
being born into oliver peoples , it & apos ; s a good way to start a conversation .
garrett leight : i have a general attraction to it , but yes , my dad is the founder of oliver peoples , which he created about 26 years ago . so i grew up in that family , and worked there as a kid doing everything from filing to just being around the glasses . being young , and in the store , i was just kind of fooling around . but i’ve always had an attraction to [ glasses ] , i’ve always loved the process and the product .
description oliver peoples
m - 4 30th
round metal sunglasses . vintage - inspired design reviving one of the first styles introduced in 1987 . hand - engraved feather pattern exclusive for the 30th anniversary collection . lens / bridge / temple ( in mm ) : 47 - 20 - 145 . flat base mirrored lenses with antireflective coating add a cool , progressive touch . silicone nose pads for comfortable fit . 100 % uva / uvb protection . made in italy . proposition 65 warning : . . .
oakley is a global leader in sport performance optics including premium sunglasses , goggles , and prescription eyewear . headquartered in southern california , the company ' s optics brand portfolio includes dragon , eye safety systems , fox racing , mosley tribes , oliver peoples , and paul smith spectacles . in addition to its global wholesale business , the company operates retail chains including bright eyes , oakley stores , sunglass icon and the optical shop of aspen . the company also offers a wide selection of oakley - branded apparel , footwear , watches and accessories . additional information is available at urltoken .
garrett leight is the first to admit that being the son of larry leight , founder of iconic , 30 - year - old eyewear brand oliver peoples , has benefited his own pursuits in the eyewear business . he learned the ropes working for his father & apos ; s company after attending college in los angeles , and while he initially wanted to break into journalism , he came to realize that eyewear was in his blood : in 2009 , he opened up an optical store ( a . kinney court ) in venice beach , then launched his own namesake brand in 2011 .
2016 was quite the year . as the calendar winds down , some people are talking about 2016 as one of the worst years in human history , or at least in recent memory . indeed , last week tonight host john oliver captured this popular opinion in the show’s year - end segment , “ fuck 2016 . ”
since the days of old hollywood , sunglasses have been key in helping celebrities maintain an air of mystery and effortlessly cool style . naturally , famous folk have preferred brands—the act of which has vaulted certain ones to icon status . ray - bans are forever , and oakleys had their day in the 90s . in the past few years , though , two brands have dominated the internationally recognizable visages of jennifer lawrence , robert downey , jr . , and even our commander in chief : oliver peoples and garrett leight . what you might not realize , however , is that these two seemingly disparate lines are actually the brainchildren of a father - son eyeglass dynasty .
i studied journalism in school . when i graduated i went to work for my dad at oliver peoples as a first job even though i wanted to work more in music or journalism , but i kind of fell in love with the environment and the company . that & apos ; s when i started to learn what an entrepreneur was and it made me thirsty to create my own environment , so i tried to absorb as much as i could from the company working in different departments — marketing , design , sales . somewhere along the line i was living in venice [ california ] and i developed this idea to open a store on abbot kinney .
there is no brand more buzz - worthy in the men’s optic game heading into this summer than garrett leight ( proof ) , which means there is no individual more buzzed about than this 28 year - old californian with an inarguable pedigree : leight’s father larry founded oliver peoples . the keys to the sunglasses kingdom weren’t as appealing to leight early on ( he had dreams of the music world ) , but fittingly enough his creations now grace the faces of the kinds of icons he emulated , and drew inspiration from . leight spoke with us about his stint as a sports journalist , the perfect pair of understated frames , and why he’ll always be buying magazines .
2016 produced a trump presidency and witnessed the rise of the “alt - right” and increasing violence against women , workers , and indigenous , lgbtq2 , and racialized peoples . 2016 also saw the approval of new pipelines , brexit , and the deaths of pop culture legends like prince , phife dawg , and david bowie and revolutionary figures like muhammad ali and fidel castro . in short , 2016 was merciless .
description oliver people
after midnight
round titanium sunglasses with linear engraving . 80 ' s inspired fashioned after the late nights in new york and styling of that era . lens / bridge / temple ( in mm ) : 49 - 22 - 145 . flat base mirrored lenses with antireflective coating add a cool , progressive touch . silicone nose pads for comfortable fit . 100 % uva / uvb protection . can be fitted with prescription lenses . made . . .
all of our frames are hand - finished in china and we source materials from all over the world — japan , italy ; our hinges are from germany . what i really learned [ from working at oliver peoples ] was that there are only two ways to make something : the right way and the wrong way . once i learned how to make eyewear the right way , we were able to manufacture the frames at a really high quality at the best price point . i started designing and developing the collection in 2009 ( which was right after the recession ) , so i was really driven to deliver a product that was significantly less expensive than the high - quality eyewear brands that i was planning on competing with . they were like $ 320 - $ 500 and i wanted to be $ 225 - $ 350 . now we’re $ 285 - $ 400 . the economy & apos ; s back , the brand & apos ; s gained a little equity and we continue to use really expensive materials , but we & apos ; re still lower than similar brands .
it was 1986 and larry leight was scouring l . a . for early u . s . eyewear brands like american optical , bausch and lomb , and ray - ban to stock his new sunset plaza boutique , launched with brother dennis . “we got lucky , ” says leight . “we found an estate sale with a room full of american brand frames in their unopened , original packaging in mint condition . i offered to buy the room . ”
the santa monica native similarly stumbled upon his career path . “college wasn’t an option for me , ” he says . “i needed to work right away to support myself . ” he enrolled in an optician program at the old downtown campus of l . a . city college . he then worked in a lab , cutting and shaping lenses , and later as a salesman and buyer for a high - end optical boutique . “as a buyer , i learned why companies were making certain styles , ” says leight , “and as a salesman , i knew what kinds sold . and those two didn’t always match up . ” with his own line leight bridges the gap , embracing the spectacled icons of the past and giving them a modern twist .
los angeles has covered the people , food , culture , arts and entertainment , fashion , lifestyle , and news that define southern california since 1961 .
write css or less and hit save . ctrl + space for auto - complete .
oakley to merge into luxottica group for us $ 29 . 30 per share | luxottica
this website or third - party tools used by the site itself use the cookies necessary for operation and useful for the objectives illustrated in the cookie policy , including the possibility of sending you advertisements according to your interests . if you want to know more or refuse consent to all or some of the cookies , consult the cookie policy .
by closing this banner , scrolling this page , clicking on a link or continuing browsing in any other way , you will agree to use of the cookies .
milan , italy and foothill ranch , calif . , june 20 , 2007 – luxottica group s . p . a . ( nyse : lux ; mta : lux ) , global leader in eyewear , and oakley , inc . ( nyse : oo ) , worldwide specialist in sport performance optics , today jointly announced that they have entered into a definitive merger agreement with the unanimous approval of both companies’ boards of directors . under the agreement , luxottica group will acquire all of the outstanding shares of oakley for a cash purchase price of us $ 29 . 30 per share , together with the purchase of all outstanding options and other equity rights at the same price per share less the exercise price . the total purchase price will be approximately us $ 2 . 1 billion , representing an approximate premium of 18 % over the 30 - day average nyse trading price of oakley shares and approximately 24 % over the three - month average trading price .
oakley’s board of directors fully supports this transaction and intends to recommend the offer to oakley’s shareholders for approval .
leonardo del vecchio , luxottica group chairman , stated , “this is a milestone for our group . significant changes in market dynamics require industry leaders to perfect a mix of best - inclass products and marketing with technical and operational capabilities . luxottica has long admired the oakley business and corporate culture , inspired by founder jim jannard . oakley and luxottica share a mutual commitment to quality , innovation , and technical skills – qualities which will help us to solidify oakley’s brand position and luxottica’s strong leadership in the market . i look forward to welcoming the talented oakley management team , led by scott olivet and colin baden , to our group . ”
luxottica will fund the payment of the purchase price and transaction costs from operating cash flow , available line of credit , and credit facilities to be available at the closing . luxottica expects its pro forma net debt / ebitda ratio for end of 2007 to be approximately 2 . 3x1 .
the transaction is expected to close in the second half of 2007 . this acquisition is subject to the approval of oakley ' s shareholders and the satisfaction of other customary conditions , including various governmental approvals .
luxottica and oakley will hold a joint conference call to discuss the proposed transaction with the investment community on thursday , june 21 , 2007 , at 8 : 00 am pdt / 11 : 00 am edt / 4 : 00 pm bst / 5 : 00 pm cet . the audio web cast will be also available at luxottica group’s corporate web site at urltoken and on oakley’s investor web site at urltoken . a replay of the conference call will be available starting on june 22 at 12 : 00 am edt , calling from usa : + 1 ( 866 ) 583 1035 , passcode 699162 # . members of the media may participate in the call in a “listen - only” mode . please note that a slide presentation will be available for download from luxottica group’s investor relations corporate web site at urltoken and on oakley’s investor web site at urltoken shortly before the start of the audio web cast .
oakley , inc . will file a proxy statement and other relevant documents concerning the proposed merger with the u . s . securities and exchange commission . oakley , inc . shareholders are urged to read the definitive proxy statement when it becomes available because it will contain important information regarding this transaction . shareholders may obtain , free of charge , a copy of the definitive proxy statement ( when it becomes available ) and other documents filed by oakley , inc . with the sec ( urltoken ) . in addition , documents filed with the sec by oakley , inc . will be available free of charge from the company . oakley , inc . and its directors and executive officers and certain other of its employees may be soliciting proxies from stockholders of oakley , inc . in favor of the proposed transaction . information concerning the participants in the proxy solicitation will be set forth in the proxy statement when it is filed with the sec .
luxottica group received investment advice from rothschild inc . and legal advice from winston & strawn llp . oakley received investment advice from goldman sachs & co . and legal advice from skadden , arps , slate , meagher & flom llp .
certain statements in this press release may constitute “forward - looking statements” as defined in the private securities litigation reform act of 1995 . such statements involve risks , uncertainties and other factors that could cause actual results to differ materially from those that are anticipated . such risks and uncertainties include , but are not limited to , the risk that the merger will not be completed , the ability to successfully introduce and market new products , the ability to maintain an efficient distribution network , the ability to predict future economic conditions and changes in consumer preferences , the ability to achieve and manage growth , the ability to negotiate and maintain favorable license arrangements , the availability of correction alternatives to prescription eyeglasses , fluctuations in exchange rates , the ability to effectively integrate recently acquired businesses , as well as other political , economic and technological factors and other risks referred to in luxottica group and oakley’s filings with the u . s . securities and exchange commission . these forward - looking statements are made as of the date hereof and , under u . s . securities regulation , neither luxottica group nor oakley assumes any obligation to update them .
such risks and uncertainties also include , but are not limited to , the occurrence of any event , change or other circumstances that could give rise to the termination of the merger agreement ; the outcome of any legal proceedings that have been , or will be , instituted related to the merger agreement ; the inability to complete the merger due to the failure to obtain oakley stockholder approval for the merger or the failure to satisfy other conditions to complete the merger , including the receipt of all regulatory approvals related to the merger ; risks that the proposed transaction disrupts current plans and operations and the potential difficulties in employee retention as a result of the merger ; the ability to recognize the benefits of the merger ; the amount of the costs , fees , expenses and charges related to the merger and the actual terms of certain financings that will be obtained for the merger .
oakley and its directors , executive officers and other members of its management and employees may be deemed participants in the solicitation of proxies from its shareholders in connection with the proposed merger . information concerning the interests of oakley participants in the solicitation , which may be different than those of oakley shareholders generally , is set forth in oakley proxy statements and annual reports on form 10 - k , previously filed with the sec , and will be set forth in the proxy statement relating to the transaction when it becomes available . investors and security holders of oakley are urged to read these materials when they become available because they will contain important information about oakley , luxottica group and the merger . the proxy statement and other relevant material ( when they become available ) and any other documents filed by oakley with the sec may be obtained free of charge by contacting oakley’s investor relations department , going to oakley’s investor web site at investor . oakley . com , or the sec’s web site at www . sec . gov .
lance allega investor relations / media relations oakley , inc . + 1 ( 949 ) 672 - 6985 lallega @ urltoken
1 the forecast of the pro forma ratio of net debt to ebitda for fiscal year 2007 is not a measure of performance under generally accepted accounting principles in the united states ( u . s . gaap ) .
voters will go to the polls on september 14 in what will mark the longest election campaign in the nation ' s history .
opposition leader tony abbott welcomes the pm ' s decision to announce the federal election will be held on september 14 .
the prime minister julia gillard during an address to the national press club , in canberra . picture : gary ramage
in a speech at the national press club prime minister gillard confirmed the election date .
the prime minister said her early announcement would allow business and consumers to
plan their year
. but it was also a challenge to the opposition to deliver policy detail sooner than it might want .
the benefit of fixing the date now is not just the end of speculation about election timing . it gives shape and order to year ,
she said .
and it enables it to be one , not of fevered campaigning but of cool and reasons deliberation .
not a year without passion – because elections are the time in our national life where values should contend , where alternate plans should be compared and considered .
no surprises also means no excuses . australians aren & apos ; t interested in campaigns without content , platitudes devoid of purpose .
there is now clearly the time … for the people and parties contesting the election to lay out their fully - detailed costed plans for the timely consideration of voters .
the prime minister will advise the governor - general to dissolve the house of representatives and issue writs on monday , august 12 for the september 14 election .
opposition leader tony abbott made a statement welcomed the announcement and said the election would be about trust .
ms gillard said she did not want to start the nation & apos ; s
longest election campaign
.
it should be clear to all which are the days of governing , and which are the days of campaigning .
ms gillard said she reflected over the summer and thought it was not right for australians to be forced into a guessing game .
she said she had consulted with her deputy wayne swan and her senior colleagues about the date .
tony abbott welcomed labor’s announcement of a poll date and declaring the campaign about trust .
repeatedly hailing his “positive plans” in front of a liberal party campaign backdrop , the opposition leader this afternoon said the coalition was ready for an election after recently launching its real solution policy platform .
“this election is about trust , ” mr abbott said , pointing to trust as important to keep the cost of living down , boosting job security and protecting the nation’s borders .
“the choice before the australian people could not be clearer . it’s more tax or less . it’s more regulation or less . it’s less competence or more . it’s less freedom of more . ”
while mr abbott focused on positivity , he did attack ms gillard’s speech before she announced the election date .
“the only real statement in the prime minister’s in her press club speech was that the australian people need to pay more tax , ” he said .
but mr abbott did not take questions at his press conference at parliament house , saying he would do so tomorrow at his national press club speech and that frontbenchers joe hockey and christopher pyne would take questions this afternoon .
ms gillard has confirmed she spoke with nsw independents tony windsor and rob oakeshott about the election date before making the announcement today .
mr oakeshott said :
i welcome the certainty of a september 14 federal election date announced . parliament runs full term , election date confirmed .
federal nsw independent mp tony windsor welcomed the announcement of the election day , saying calling it now would provide certainty .
but he admitted the early announcement would mean the next eight months might well see both major parties in campaign mode .
in the past , australians have been frustratingly on & apos ; election alert & apos ; for long periods of time and , in this & apos ; hung & apos ; parliament , on the brink of an election from day one if you believe the opposition leader and some sections of the media ,
he said in a statement .
shadow treasurer joe hockey was concerned about the state of the budget which a coalition government might inherit .
election on sept 14 is before the final budget outcome is revealed for the current year ,
he tweeted .
mr hockey also tweeted :
julia gillard is giving herself certainty about the election date but won & apos ; t give australian families certainty about ` savings & apos ; impacts
. liberal frontbencher malcolm turnbull said : “deeply disappointed that julia gillard chose to hold the election on yom kippur - the most solemn and sacred day of the jewish year . ”
influential liberal mp josh frydenberg echoed the concern , taking to twitter to say
this disenfranchises many jewish australians and is incredibly sloppy work
.
“bring it on . bring it on . bring it on ! ” mr perrett said .
so , the fed election is on sept 14 - how much more damage can labor do in 7 months ?
he tweeted .
the greens say they will seek a multi - party commitment to adopt fixed - term elections .
kevin rudd has declared he will campaign in every state to help government & apos ; s re - election chances .
but the former prime minister has refused to answer several questions about the woman who deposed him , including her decision to set an election date so early .
mr rudd said he had already been asked by local mps to campaign in every state .
when asked about his own leadership intentions , mr rudd said he had already made them clear last february .
last february he promised not to run against ms gillard again after she resoundingly won a leadership ballot .
the coalition is a firm favourite with at least one bookmaker to win the september election .
punters are putting money on the coalition to win the september 14 federal election with their odds cut to $ 1 . 22 from $ 1 . 26 within hours of ms gillard announcing the date .
sportingbet australia chief executive michael sullivan said if the pm was anticipating a positive reaction to her election announcement , she may be surprised . punters have responded by backing the coalition into even shorter odds .
we actually thought there would be some support for the alp after the announcement , & apos ; & apos ; mr sullivan said in a statement . labor & apos ; s odds drifted from $ 3 . 75 to $ 4 . 15 .
we can & apos ; t find anyone interested in backing them , & apos ; & apos ; he said .
a jws research poll of 54 marginal seats predicted federal labor could lose 18 seats and its hold on government .
city index chief market analyst peter esho said selection of saturday , september 14 as the date for the next federal election was unsurprising .
that & apos ; s within the ballpark range of probable dates that most forecasters were assuming ,
mr esho said .
everyone was assuming that this government would try to go as long as it can into its term , so there & apos ; s no real surprise with september .
the australian stock market and dollar had a muted reaction to ms gillard & apos ; s poll date announcement , which came shortly before 1pm aedt .
mr esho said the decision to go to the polls in september could indicate the federal government was not too concerned about its budget situation .
he said there had been no policy announcements accompanying the announcement of the election date , which might indicate that the government could have some surprises up its sleeve when treasurer wayne swan announces the federal budget on may 14 .
one of the biggest issues weighing on the market has been political instability , not necessarily who holds government ,
mr esho said .
the prime minster began her speech , which outlined her priorities for 2013 , by declaring most australians fear our children will not lead a better life than themselves .
i want this audience to feel all the force of that concern . i most certainly do , the prime minister told the national press club in canberra .
ms gillard pointed to insecurity for many following the global financial crisis , and extra pressures fro the ordeal of long commutes to work to paying household bills .
it means it can be a struggle to make ends meet and it can seem far harder to get ahead in the post - gfc world ,
she said .
it means we are more likely than earlier generations to face the challenges of parenting and caring for older parents at the same time .
combined with the travel time to work and , for some , concern about community safety , life can be very stressed and pressurised .
through all this , we are more connected with information about world events and causes of community anxiety than ever before .
over time , the uncertainties and pressures we live with have led some of us to be concerned that our children won & apos ; t live a better life than us .
the speech highlighted families as a priority for labor and the focus of broader economic policy this election year with the prime minister pledging to make the next generation
stronger , fairer , smarter
.
as a generation of australians , our greatest task , our highest calling , is to build a future of greater shared opportunity and less risk for the next generation ,
said ms gillard .
i want to eradicate any sense we can & apos ; t get this done . as a nation , we are strong , fair by instinct , smart .
i know that we have it within us to ensure the next generation of australians is stronger , fairer , smarter . i am an optimist ; everything we have achieved as a nation reinforces that optimism , everything we are planning delivers on it .
but ms gillard foreshadowed tough budget measures - what she called
long - term saving measures
- to pay for that security by warning that governments were facing their toughest revenue raising periods for years .
as expected , she nominated increased school funding and creation of a national disability insurance scheme as the destinations for much of the savings , but did not in her speech say where the cuts would be made .
the prime minister said government revenue per unit of national output was at the lowest since the early 1990s .
in other words , for a given amount of economic income generated , less money is finishing in the public purse , to be used for the australian people ,
she said .
we are experiencing a proportional reduction in the amount of revenue being generated from any given amount of economic income . this is part of a trend which is felt worldwide .
now , the immediate effect of this was made clear by the deputy prime minister ( treasurer wayne swan ) last december .
while within our medium - term fiscal strategy , spending is tightly constrained , the amount of tax collected from all sources - particularly from company tax - is significantly lower than independent forecasters or the treasury have anticipated .
compared to the public revenue which was forecast on the eve of the global financial crisis in 2008 , what has actually been collected in tax since is far lower - on average , lower by more than $ 30 billion every year .
even compared to what was forecast once the worst of the global financial crisis had passed , annual revenue is tens of billions of dollars below what was expected .
evie amati : trial starts of woman accused of axe attack caug . . .
a note about relevant advertising : we collect information about the content ( including ads ) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites . find out more about our policy and your choices , including how to opt - out .
news limited copyright © 2018 . all times aest ( gmt + 10 ) .
html public
- / / w3c / / dtd xhtml 1 . 0 transitional / / en
urltoken
we are partnering with someone whose products are a little more premium , a little more fashionable and in a zone of the market that would not be appropriate for us to do with the oakley brand ,
chief executive scott olivet said .
so we looked at who would be a great partner in that and we found them .
analysts described the deal as a marriage of opposites that made sense on a number of levels . oakley is known for cutting - edge technology and optics and its flashy advertisements , many featuring athletes such as seven - time tour de france winner lance armstrong , skateboard champion ryan sheckler and snowboarding champion laura hadar . last year oakley introduced a line of eyewear equipped with bluetooth cellular technology , which allows hands - free wireless communication .
that was a primary reason for agreeing to the sale , said leight , noting that his three brands go head - to - head with deep - pocketed competitors such as dior , gucci and chanel .
i can ' t achieve our vision and our dreams operating as a family business ,
leight said of his 53 - employee operation .
it was the right time to attract the right buyer .
oakley said the deal had been completed with the approval of founder and chairman jim jannard , who owns 64 % of shares .
oakley announced the deal after markets closed . its shares rose 32 cents to $ 16 . 24 in regular trading and were little changed after hours . the company is scheduled to announce fourth - quarter and full - year 2005 earnings today .
how to update some of your winter staples so they work for . . .
: there are no more barriers to cross . all i have in common with the uncontrollable and the insane , the vicious and the evil , all the mayhem i have caused and my utter indifference toward it i have now surpassed . my pain is constant and sharp , and i do not hope for a better world for anyone . in fact , i want my pain to be inflicted on others . i want no one to escape . but even after admitting this , there is no catharsis ; my punishment continues to elude me , and i gain no deeper knowledge of myself . no new knowledge can be extracted from my telling . this confession has meant nothing .
: i like to dissect girls . did you know i ' m utterly insane ?
: howard , it ' s bateman , patrick bateman . you ' re my lawyer so i think you should know : i ' ve killed a lot of people . some girls in the apartment uptown uh , some homeless people maybe 5 or 10 um an nyu girl i met in central park . i left her in a parking lot behind some donut shop . i killed bethany , my old girlfriend , with a nail gun , and some man uh some old faggot with a dog last week . i killed another girl with a chainsaw , i had to , she almost got away and uh someone else there i can ' t remember maybe a model , but she ' s dead too . and paul allen . i killed paul allen with an axe in the face , his body is dissolving in a bathtub in hell ' s kitchen . i don ' t want to leave anything out here . i guess i ' ve killed maybe 20 people , maybe 40 . i have tapes of a lot of it , uh some of the girls have seen the tapes . i even , um . . . i ate some of their brains , and i tried to cook a little . tonight i , uh , i just had to kill a lot of people . and i ' m not sure i ' m gonna get away with it this time . i guess i ' ll uh , i mean , ah , i guess i ' m a pretty uh , i mean i guess i ' m a pretty sick guy . so , if you get back tomorrow , i may show up at harry ' s bar , so you know , keep your eyes open .
: i ' m into , uh , well , murders and executions , mostly .
: well , most guys i know who are in mergers and acquisitions really don ' t like it .
: their early work was a little too new wave for my tastes , but when sports came out in ' 83 , i think they really came into their own , commercially and artistically . the whole album has a clear , crisp sound , and a new sheen of consummate professionalism that really gives the songs a big boost . he ' s been compared to elvis costello , but i think huey has a far more bitter , cynical sense of humor .
: yes it is ! in ' 87 , huey released this , fore , their most accomplished album . i think their undisputed masterpiece is
hip to be square
, a song so catchy , most people probably don ' t listen to the lyrics . but they should , because it ' s not just about the pleasures of conformity , and the importance of trends , it ' s also a personal statement about the band itself .
: there is an idea of a patrick bateman ; some kind of abstraction . but there is no real me : only an entity , something illusory . and though i can hide my cold gaze , and you can shake my hand and feel flesh gripping yours and maybe you can even sense our lifestyles are probably comparable . . . i simply am not there .
: you ' re a fucking ugly bitch . i want to stab you to death , and then play around with your blood .
: i live in the american gardens building on w . 81st street on the 11th floor . my name is patrick bateman . i ' m 27 years old . i believe in taking care of myself and a balanced diet and rigorous exercise routine . in the morning if my face is a little puffy i ' ll put on an ice pack while doing stomach crunches . i can do 1000 now . after i remove the ice pack i use a deep pore cleanser lotion . in the shower i use a water activated gel cleanser , then a honey almond body scrub , and on the face an exfoliating gel scrub . then i apply an herb - mint facial mask which i leave on for 10 minutes while i prepare the rest of my routine . i always use an after shave lotion with little or no alcohol , because alcohol dries your face out and makes you look older . then moisturizer , then an anti - aging eye balm followed by a final moisturizing protective lotion .
: i ' m fucking serious . it ' s fucking over , us , this is no joke . i don ' t think we should see each other any more .
: but your friends are my friends and my friends are your friends . i really don ' t think it would work . you have a little something . . .
: i know that your friends are my friends and , uh . . . i ' ve thought about that . you can have ' em .
:
when i see a pretty girl walking down the street , i think two things . one part wants me to take her out , talk to her , be real nice and sweet and treat her right .
:
what her head would look like on a stick . . .